Dr. Reddy's Lab is poised to witness crosswinds from a drop in revenue from the patent expiration of Revlimid and increased ...

Stay up-to-date with the Dr Reddys Stock Liveblog, your comprehensive source for real-time updates and detailed analysis on a prominent stock. Explore the latest information on Dr Reddys, including: ...

Welcome to the Dr Reddys Stock Liveblog, your ultimate source for real-time updates and analysis of one of the most prominent ...

Dr. Reddy's Laboratories Ltd. closed 16.92% below its 52-week high of 1,420.20 rupees, which the company reached on August ...

Crossmark Global Holdings Inc. grew its stake in shares of Dr. Reddy’s Laboratories Limited (NYSE:RDY – Free Report) by 328.3% in the fourth quarter, Holdings Channel reports. The firm owned 12,760 ...

Dr. Reddy's Laboratories Ltd. 500124 shares slipped 2.23% to 1,197.40 Indian rupees Monday, on what proved to be an ...

Barclays analyst Balaji Prasad maintained a Buy rating on Dr Reddy’s Laboratories (RDY – Research Report) today and set a price target of ...

Dr Reddy's Laboratories (DRL) share price plunged 6.66 per cent to Rs 1,203.50 per share on the NSE during Friday after ...

Indian generic drugmaker Dr Reddys Laboratories expressed optimism about the Donald Trump administration on Thursday, citing ...

Dr. Reddy's stock falls on Q3 fiscal 2025 results, wherein earnings match estimates but revenues beat the same.

Dr Reddy’s Laboratories share price declined more than 6% in the morning trades on Friday post Q3 results that were announced after the market hours of Thursday ...

Donald Trump's swearing-in ceremony, Davos and Q3 earnings are among the major events that took place this week.